Matteo Giovanni Della Porta

Medicine & Life Sciences

1. Myelodysplastic Syndromes 100%
2. Mutation 18%
3. Survival 17%
4. Hematopoietic Stem Cell Transplantation 16%
5. Hematologic Neoplasms 15%
6. Italy 11%
7. Bone Marrow 11%
8. Genes 10%
9. Acute Myeloid Leukemia 10%
10. Primary Myelofibrosis 10%
11. Multicenter Studies 9%
12. Flow Cytometry 9%
13. Iron 9%
14. SARS Virus 8%
15. Neoplasms 8%
16. Cohort Studies 8%
17. Cytogenetics 8%
18. Chromosome 5q Deletion Syndrome 7%
19. Decision Support Techniques 7%
20. Leukemia, Myelomonocytic, Chronic 7%
21. Refractory Anemia 7%
22. Dendritic Cells 6%
23. Myeloproliferative Disorders 6%
24. Life Expectancy 6%
25. Stem Cell Transplantation 6%
26. Ferritins 6%
27. Mortality 6%
28. Azacitidine 6%
29. Polycythemia Vera 6%
30. GATA2 Deficiency 6%
31. Hematology 6%
32. Karyotype 6%
33. Risk Assessment 6%
34. Deferasirox 6%
35. Trabectedin 5%
36. INCB018424 5%
37. Comorbidity 5%
38. Therapeutics 5%
39. Genomic Instability 5%
40. Transplantation 5%
41. B-Cell Chronic Lymphocytic Leukemia 5%
42. Fluorescence In Situ Hybridization 5%